NVCR - NovoCure: A Long-Term Hold At A Competitive Price
Investment thesis
NovoCure (NVCR) has made impressive progress in developing and commercialising its novel and innovative Tumor Treating Fields therapy technology, which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division, administered via a head-worn connected medical device.
NovoCure 5-year share price performance: Source: TradingView
The company won approval from the FDA for its second-generation Optune delivery system in 2015 on the back of successful trials in combination with chemotherapy treatment temozolomide which showed that Optune plus temozolomide increased 5-year survival rates of patients with newly diagnosed glioblastoma multiforme ("GBM")